骨质疏松症治疗:近期进展与持续挑战
本文回顾了骨质疏松症药物治疗的演变:从20世纪40年代 Albright 证明雌激素可逆转绝经或卵巢切除后女性的负钙平衡,到2000年前后药物发现模式转向基础骨生物学与罕见骨病线索驱动。尽管治疗取得巨大进展,但对抗吸收药物罕见副作用的担忧及长期疗效证据不足导致治疗缺口扩大,亟需提高患者接受度和依从性并开发无此类副作用且具持久合成代谢作用的新药。
要点
- 骨质疏松症已从不可避免的衰老后果转变为可预防可治疗的疾病。
- 2000年前后药物发现模式从动物研究和临床观察驱动转向基础骨生物学和罕见骨病线索驱动。
- 对双膦酸盐等抗吸收药物罕见副作用的担忧和长期疗效证据不足导致高危患者治疗缺口扩大。
核心结论
- 尽管治疗取得巨大进展,高骨折风险患者的治疗缺口仍在扩大,亟需提高患者对有效药物的接受度和依从性,并继续开发不引起这些副作用且对骨具有持久合成代谢作用的新药。
研究设计与样本
- 本文为系列综述,回顾骨质疏松症药物治疗的演变历程。
主要发现
- 20世纪40年代 Fuller Albright 证明雌激素治疗可逆转绝经或卵巢切除后女性出现的负钙平衡。
- 2000年前后骨质疏松症药物发现模式发生分水岭式转变:从动物研究和临床观察驱动(如雌激素、降钙素、特立帕肽)或现有化合物机会性再利用(如双膦酸盐),转向基础骨生物学进展驱动(如地舒单抗)并结合罕见骨病患者线索(如罗莫佐单抗、奥达卡替)。
- 对双膦酸盐等抗吸收药物罕见副作用的担忧及长期疗效明确证据的缺乏,导致许多本可从药物治疗获益的患者未服用这些药物。
局限性
- 原文指出抗吸收药物(尤其是双膦酸盐)的长期疗效缺乏明确证据支持。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Osteoporosis is an enormous and growing public health problem. Once considered an inevitable consequence of ageing, it is now eminently preventable and treatable. Ironically, despite tremendous therapeutic advances, there is an increasing treatment gap for patients at high fracture risk. In this Series paper, we trace the evolution of drug therapy for osteoporosis, which began in the 1940s with the demonstration by Fuller Albright that treatment with oestrogen could reverse the negative calcium balance that developed in women after menopause or oophorectomy. We note a watershed in osteoporosis drug discovery around the year 2000, when the approach to developing novel therapeutics shifted from one driven by discoveries in animal studies and clinical observations (eg, oestrogen, calcitonin, and teriparatide) or opportunistic repurposing of existing compounds (eg, bisphosphonates) to one driven by advances in fundamental bone biology (eg, denosumab) coupled with clues from patients with rare bone diseases (eg, romosozumab, odanacatib). Despite these remarkable advances, concerns about rare side-effects of anti-resorptive drugs, particularly bisphosphonates, and the absence of clear evidence in support of their long-term efficacy is leading many patients who could benefit from drug therapy to not take these drugs. As such, there remains an important clinical need to develop ways to enhance patient acceptance and compliance with these effective drugs, and to continue to develop new drugs that do not cause these side-effects and have prolonged anabolic effects on bone. Such changes could lead to a true reversal of this potentially devastating disease of ageing.
引用
- Khosla S, Hofbauer LC. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol. 2017. PMID: 28689769. doi:10.1016/S2213-8587(17)30188-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。